Live Bacteria Therapy for TB Immunotherapy Using Ag85AB as Vector and Targeted Liposome Delivery system
Fuente:
Zenodo
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2026
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901748798455808 |
|---|---|
| author | Amimo, Lesley Agyemang, Aurora Adwubi Matabori, Sarah Nyarangi Anim, Grace Kwaku |
| author_facet | Amimo, Lesley Agyemang, Aurora Adwubi Matabori, Sarah Nyarangi Anim, Grace Kwaku |
| contents | <p>This project proposes a novel synthetic biology-based therapeutic strategy for tuberculosis (TB), addressing the critical limitations of current treatment approaches including multidrug resistance (MDR/RR-TB), prolonged treatment durations, and therapy-induced dysbiosis. With TB affecting approximately 22% of the global population and over 10.6 million new cases reported in 2021 (WHO Global Tuberculosis Report 2022), there is an urgent need for innovative treatment alternatives.</p> <p>The proposed intervention combines live bacteria therapy with a targeted liposome delivery system, using <em>Lactobacillus</em> as a vector engineered to carry the Ag85A/B plasmid (pVAX1, 3.0 kb). The Ag85A and Ag85B antigens are well-characterized immunogenic proteins of <em>Mycobacterium tuberculosis</em> known to stimulate robust cellular immune responses. Once delivered via inhalation through targeted liposomes, the live bacteria are engulfed by macrophages, triggering antigen presentation and activating both CD4+ and CD8+ T-cell mediated immunity.</p> <p>Key advantages of this approach include dual utility as both a vaccine and immunotherapy agent, targeted pulmonary delivery, long-lasting immune protection through bacterial persistence, and reduced need for repeated dosing. Biosafety considerations and limitations — particularly for immunocompromised populations such as HIV-positive patients — are also discussed, along with the variability of host immune responses as a challenge to consistent therapeutic outcomes.</p> <p>This work was conducted as part of the Synthetic Biology for All (SynBio for All) program.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18878318 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Live Bacteria Therapy for TB Immunotherapy Using Ag85AB as Vector and Targeted Liposome Delivery system Amimo, Lesley Agyemang, Aurora Adwubi Matabori, Sarah Nyarangi Anim, Grace Kwaku Synthetic Biology Tuberculosis Multi-drug resistance Lactobacillus Liposome TB Immunotherapy Antigen Delivery T-cell Activation <p>This project proposes a novel synthetic biology-based therapeutic strategy for tuberculosis (TB), addressing the critical limitations of current treatment approaches including multidrug resistance (MDR/RR-TB), prolonged treatment durations, and therapy-induced dysbiosis. With TB affecting approximately 22% of the global population and over 10.6 million new cases reported in 2021 (WHO Global Tuberculosis Report 2022), there is an urgent need for innovative treatment alternatives.</p> <p>The proposed intervention combines live bacteria therapy with a targeted liposome delivery system, using <em>Lactobacillus</em> as a vector engineered to carry the Ag85A/B plasmid (pVAX1, 3.0 kb). The Ag85A and Ag85B antigens are well-characterized immunogenic proteins of <em>Mycobacterium tuberculosis</em> known to stimulate robust cellular immune responses. Once delivered via inhalation through targeted liposomes, the live bacteria are engulfed by macrophages, triggering antigen presentation and activating both CD4+ and CD8+ T-cell mediated immunity.</p> <p>Key advantages of this approach include dual utility as both a vaccine and immunotherapy agent, targeted pulmonary delivery, long-lasting immune protection through bacterial persistence, and reduced need for repeated dosing. Biosafety considerations and limitations — particularly for immunocompromised populations such as HIV-positive patients — are also discussed, along with the variability of host immune responses as a challenge to consistent therapeutic outcomes.</p> <p>This work was conducted as part of the Synthetic Biology for All (SynBio for All) program.</p> |
| title | Live Bacteria Therapy for TB Immunotherapy Using Ag85AB as Vector and Targeted Liposome Delivery system |
| topic | Synthetic Biology Tuberculosis Multi-drug resistance Lactobacillus Liposome TB Immunotherapy Antigen Delivery T-cell Activation |
| url | https://doi.org/10.5281/zenodo.18878318 |